ERBB2 and breast carcinoma: In an immunocompetent syngeneic mouse model of ErbB2-induced breast cancer, we next show that carbonic anhydrase inhibitors (c) acidify the tumor microenvironment, (d) lower immune infiltration and chronic tumor inflammation, and (e) accelerate tumor growth.